📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
NEUTRAL
score: 0.17
SENTIMENT
NEUTRAL
TOTAL VIEWS
61
RXRX Stock Analysis & AI Grade: NEUTRAL
3 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 3 ARTICLES
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
Recursion Pharmaceuticals (RXRX) has attracted a $50 million position from Cathie Wood's Ark Genomic Revolution ETF (ARKG), signaling...
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) experienced a 3.13% decline in the most recent session, underperforming the broader market and...
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Moderna (MRNA) and Recursion (RXRX) represent divergent approaches to pharmaceutical innovation, with the former leveraging established...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice